78 related articles for article (PubMed ID: 688281)
1. Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy.
Hubbard SM; Barkes P; Young RC
Cancer Treat Rep; 1978 Sep; 62(9):1375-7. PubMed ID: 688281
[No Abstract] [Full Text] [Related]
2. Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary.
de Palo GM; de Lena M; Di Re F; Luciani L; Valagussa P; Bonadonna G
Surg Gynecol Obstet; 1975 Dec; 141(6):899-902. PubMed ID: 1103333
[TBL] [Abstract][Full Text] [Related]
3. [Preliminary report on the treatment of ovarian cancer with adriamycin following full conventional treatment (author's transl)].
Wolf A; Vahrson H
Geburtshilfe Frauenheilkd; 1977 Mar; 37(3):224-7. PubMed ID: 858485
[TBL] [Abstract][Full Text] [Related]
4. Adriamycin versus adriamycin plus melphalan in advanced ovarian carcinoma.
De Palo GM; De Lena M; Bonadonna G
Cancer Treat Rep; 1977; 61(3):355-7. PubMed ID: 326402
[No Abstract] [Full Text] [Related]
5. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
6. [A combination of cyclophosphamide, adriamycin and platinum (CAP) in the treatment of stage III and IV ovarian cancer].
Chylak V; Krusić J; Kolarić K
Jugosl Ginekol Perinatol; 1988; 28(1-2):41-3. PubMed ID: 3398564
[No Abstract] [Full Text] [Related]
7. [Combined chemo- and hormone-therapy in advanced ovarian carcinoma--theoretical, experimental foundations and clinical results].
Sevelda P
Wien Klin Wochenschr Suppl; 1990; 183():3-29. PubMed ID: 2145702
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
[TBL] [Abstract][Full Text] [Related]
9. [Experience with adriamycin in the treatment of advanced breast and ovarian cancer (author's transl)].
Kolarić K; Maricić Z ; Krusić J; Nola P
Lijec Vjesn; 1976 Jun; 98(6):313-16. PubMed ID: 790065
[No Abstract] [Full Text] [Related]
10. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel-anthracycline combination chemotherapy in relapsing advanced ovarian cancer after platinum-based chemotherapy: a pilot study.
Kurtz JE; Deplanque G; Duclos B; Eichler F; Giron C; Limacher JM; Herbrecht R; Maloisel F; Oberling F; Bergerat JP; Dufour P
Gynecol Oncol; 1998 Sep; 70(3):414-7. PubMed ID: 9790797
[TBL] [Abstract][Full Text] [Related]
12. Excellent progression-free survival with liposomal doxorubicin for a patient with recurrent ovarian malignant mixed müllerian tumor: case report and literature review.
Hsieh CL; Chang TC; Lai CH; Jung SM; Chou HH
Gynecol Oncol; 2004 Sep; 94(3):854-7. PubMed ID: 15350389
[TBL] [Abstract][Full Text] [Related]
13. Polychemotherapy in ovarian cancer: treatment with Adriamycin, BCNU and cyclophosphamide vs. Adriamycin and cyclophosphamide.
Mazzei T; Bonazza M; Amunni G; Scarselli G; Branconi F; Massi GB
Chemioterapia; 1984 Feb; 3(1):10-5. PubMed ID: 6535650
[TBL] [Abstract][Full Text] [Related]
14. 4'-epi-doxorubicin in combination with cisplatin in advanced ovarian cancer.
Martoni A; Tomasi L; Farabegoli G; Fruet F; Pannuti F
Cancer Treat Rep; 1984 Nov; 68(11):1391-3. PubMed ID: 6594196
[TBL] [Abstract][Full Text] [Related]
15. High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group.
Sikic BI; Scudder SA; Ballon SC; Soriero OM; Christman JE; Suey L; Ehsan MN; Brandt AE; Evans TL
Semin Oncol; 1986 Dec; 13(4 Suppl 4):26-32. PubMed ID: 3099393
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen therapy for advanced ovarian cancer.
Schwartz PE; Keating G; MacLusky N; Naftolin F; Eisenfeld A
Obstet Gynecol; 1982 May; 59(5):583-8. PubMed ID: 7070729
[TBL] [Abstract][Full Text] [Related]
17. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
Gossner G; Coleman RL; Mutch DG; Horowitz NS; Rader JS; Gibb RK; Powell MA; Herzog TJ
Gynecol Oncol; 2006 Oct; 103(1):212-8. PubMed ID: 16677696
[TBL] [Abstract][Full Text] [Related]
18. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
Pignata S; Scambia G; Pisano C; Breda E; Di Maio M; Greggi S; Ferrandina G; Lorusso D; Zagonel V; Febbraro A; Riva N; De Rosa V; Gallo C; Perrone F;
Br J Cancer; 2007 Jun; 96(11):1639-43. PubMed ID: 17486128
[TBL] [Abstract][Full Text] [Related]
19. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
Rose PG
Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
[TBL] [Abstract][Full Text] [Related]
20. Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy.
Zidan J; Zohar S; Mijiritzky I; Kral S; Bilenca B
Isr Med Assoc J; 2002 Aug; 4(8):597-9. PubMed ID: 12183859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
